Envafolimab plus chemoradiation and endostatin for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of a new immunotherapy (envafolimab) with standard chemoradiation and a drug that blocks blood vessel growth (endostatin) for people with advanced nasopharyngeal cancer that hasn't been treated before. The goal is to see if this combination works better than the usual treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your cancer is locally advanced (stage III or IVA) and has not spread to other parts of the body.
- You have not had any prior radiation or chemotherapy for this cancer.
- You are able to do most daily activities without help (ECOG 0-1).
- You are willing to provide a tumor tissue sample and have blood tests for PD-L1 and EBV.
- You are not pregnant or breastfeeding, and you do not have active hepatitis B or C, HIV, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
This trial tests a combination of three treatments—a targeted cancer drug (becotatug vedotin), an immunotherapy drug (PD-1 antibody), and radiation therapy—for nasopharyngeal cancer that has come back after initial treatment. The goal is to see if this combination can shrink the tumor and help you live longer.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This trial tests a combination of three drugs—chemotherapy (gemcitabine), a blood-vessel blocker (Endostar), and an immunotherapy (Envafolimab)—for older adults with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard care for patients aged 65 and up.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.